ADVANCED ENDOMETRIAL CANCER
Clinical trials for ADVANCED ENDOMETRIAL CANCER explained in plain language.
Never miss a new study
Get alerted when new ADVANCED ENDOMETRIAL CANCER trials appear
Sign up with your email to follow new studies for ADVANCED ENDOMETRIAL CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Engineered immune cells take on Hard-to-Treat ovarian and endometrial cancers
Disease control Not yet recruitingThis early-phase trial tests a one-time treatment called OPB-201, where a patient's own immune cells are modified in a lab to better recognize and attack cancer cells that carry a protein called PRAME. The study will enroll 30 adults with recurrent endometrial cancer or platinum-…
Matched conditions: ADVANCED ENDOMETRIAL CANCER
Phase: PHASE1 • Sponsor: Outpace Bio, Inc. • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New drug cocktail aims to fight advanced uterine cancer
Disease control Not yet recruitingThis Phase 3 trial tests whether adding the drug EG-007 to a standard combination of lenvatinib and pembrolizumab helps people with advanced or recurrent endometrial cancer live longer without their cancer growing. About 450 participants will be randomly assigned to receive eithe…
Matched conditions: ADVANCED ENDOMETRIAL CANCER
Phase: PHASE3 • Sponsor: Evergreen Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:02 UTC
-
New hope for advanced endometrial cancer: Triple-Drug combo enters safety testing
Disease control Not yet recruitingThis phase 2 trial tests whether adding a repurposed drug called EG-007 to the standard combination of lenvatinib and pembrolizumab is safe for people with advanced or recurrent endometrial cancer. The study will enroll 28 adults whose cancer has progressed after platinum chemoth…
Matched conditions: ADVANCED ENDOMETRIAL CANCER
Phase: PHASE2 • Sponsor: Evergreen Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:02 UTC